Study rationale and design of ADVANCE: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation

Medicine and Dentistry

• ACE Inhibitor 25%
• Apoplexy 25%
• Blood Pressure 100%
• Cardiovascular System 25%
• Diabetes 100%
• Diabetes Mellitus 25%
• Diuretics 25%
• Eye Disease 25%
• Gliclazide 100%
• Glucose 75%
• Glycemic Control 25%
• Indapamide 50%
• Indapamide Plus Perindopril 100%
• Macrovascular Disease 75%
• Maturity Onset Diabetes of the Young 50%
• Microangiopathy 75%
• Myocardial Infarction 25%
• Nephropathy 25%
• Patient with Type 2 Diabetes 25%
• Perindopril 50%
• Placebo 25%
• Randomized Controlled Trial 25%
• Sulfonylurea 25%
• Treatment Duration 25%
• Vascular Disease 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Cerebrovascular Accident 33%
• Diabetes Mellitus 33%
• Dipeptidyl Carboxypeptidase Inhibitor 33%
• Diseases 33%
• Diuretics 33%
• Eye Disease 33%
• Gliclazide 100%
• Glucose 100%
• Heart Infarction 33%
• Indapamide 66%
• Indapamide Plus Perindopril 100%
• Kidney Disease 33%
• Maturity Onset Diabetes of the Young 100%
• Microangiopathy 100%
• Perindopril 66%
• Placebo 33%
• Randomized Controlled Trial 33%
• Sulfonylurea 33%
• Vascular Disease 100%

Keyphrases

• Non-insulin-dependent Diabetes Mellitus (NIDDM) 33%
• Pressure Concentration 33%